Sign In
Buy RPRX
$56.45
+0.0200 (+0.0354%)
At Close: Jul 13, 2026
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Monday, 13'th Jul 2026
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again
01:10pm, Friday, 10'th Jul 2026
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice
01:01pm, Friday, 10'th Jul 2026
Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 10'th Jul 2026
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RPRX or ACAD: Which Is the Better Value Stock Right Now?
12:40pm, Thursday, 09'th Jul 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the bes
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
06:22pm, Tuesday, 09'th Jun 2026
Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
01:16pm, Tuesday, 09'th Jun 2026
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
06:19pm, Friday, 05'th Jun 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
04:15pm, Thursday, 04'th Jun 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
12:50pm, Tuesday, 19'th May 2026
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
03:12am, Saturday, 16'th May 2026
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:10pm, Wednesday, 13'th May 2026
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma to present at upcoming investor conferences
04:15pm, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
RPRX vs. AMGN: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 06'th May 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the be
